Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial - Takeaways - MDSpire

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • By

  • Hao-Rui Shen

  • Jia-Zhu Wu

  • Hua Yin

  • Kai-Xin Du

  • Luthuli Sibusiso

  • Yi-Fan Wu

  • Wei Hua

  • Yue Li

  • Yi-Lin Kong

  • Xin-Yu Zhang

  • Rui Gao

  • Jian-Yong Li

  • Li Wang

  • Jin-Hua Liang

  • Wei Xu

  • February 11, 2026

  • 0 min

Share

  • 1

    Primary central nervous system lymphoma (PCNSL) is a B-cell non-Hodgkin lymphoma with a poor prognosis and a median survival of 1-2 years.

  • 2

    High-dose methotrexate (HD-MTX) is the standard induction therapy for PCNSL, often combined with other agents like cytarabine and rituximab.

  • 3

    Penpulimab, a humanized IgG1 monoclonal antibody targeting PD-1, is designed to reduce immune-related adverse events compared to traditional PD-1 inhibitors.

  • 4

    A phase 2 study evaluated the Pen-RMA regimen, combining penpulimab with rituximab, HD-MTX, and cytarabine, showing promising efficacy in newly diagnosed PCNSL.

  • 5

    The study reported an overall response rate of 96.3% with significant 2-year progression-free and overall survival rates in patients treated with Pen-RMA.

Original Source(s)

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • by Hao-Rui Shen, Jia-Zhu Wu, Hua Yin, Kai-Xin Du, Luthuli Sibusiso, Yi-Fan Wu, Wei Hua, Yue Li, Yi-Lin Kong, Xin-Yu Zhang, Rui Gao, Jian-Yong Li, Li Wang, Jin-Hua Liang, Wei Xu

  • February 11, 2026

Related Content

Genomic landscape and molecular subtypes of primary central nervous system lymphoma

Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study